Yazhong Huang

US Patent:

6875771, Apr 5, 2005

Filed:

Jul 15, 2003

Appl. No.:

10/620240

Inventors:

Yong-Jin Wu - Madison CT, US
Shuanghua Hu - Milford CT, US
Paul M. Scola - Glastonbury CT, US
Yazhong Huang - West Haven CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D487/02
A61K031/519

US Classification:

5142594, 51425941, 514267, 544250, 544252, 544282

Abstract:

Novel pyridopyrimidine derivatives which have a binding affinity for the human 5-HTreceptor and, therefore, are useful in treating disorders responsive to antagonism of the 5-HTreceptor such as psychosis, schizophrenia, manic depression, depression, neurological disorder, memory disorder, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's chorea.

US Patent:

7179926, Feb 20, 2007

Filed:

Jul 25, 2005

Appl. No.:

11/188581

Inventors:

Yazhong Huang - Branford CT, US
Shuanghua Hu - Milford CT, US
Andrew P. Degnan - New Haven CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 333/16
C07D 333/46
C07C 211/00
C07C 217/44
C07C 321/06
A61K 31/135
A61K 31/38

US Classification:

549 75, 564340, 564346, 564367, 514438, 514649, 514651, 514654

Abstract:

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts and solvates, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.

US Patent:

8354548, Jan 15, 2013

Filed:

Feb 11, 2011

Appl. No.:

13/025674

Inventors:

Shuanghua Hu - Milford CT, US
Yazhong Huang - Branford CT, US
Min Ding - Glastonbury CT, US
Louis S. Chupak - Old Saybrook CT, US
Xiaofan Zheng - Cheshire CT, US
Robert G. Gentles - Wallingford CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 311/00

US Classification:

549409

Abstract:

The present disclosure is generally directed to compounds that can inhibit DAGLα and/or β activity, compositions comprising such compounds, and methods for inhibiting DAGLα and/or β activity.

US Patent:

8404741, Mar 26, 2013

Filed:

Feb 11, 2011

Appl. No.:

13/025384

Inventors:

Louis S. Chupak - Old Saybrook CT, US
Xiaofan Zheng - Cheshire CT, US
Min Ding - Glastonbury CT, US
Shuanghua Hu - Milford CT, US
Yazhong Huang - Branford CT, US
Robert G. Gentles - Wallingford CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A01N 43/16
A01N 37/12
A01N 37/44
A61K 31/35
A61K 31/195
C07D 317/70
C07C 51/16
C07C 229/00

US Classification:

514456, 514567, 549433, 562407, 562456

Abstract:

The present disclosure is generally directed to compounds that can inhibit DAGLα and/or β activity, compositions comprising such compounds, and methods for inhibiting DAGLα and/or β activity.

US Patent:

60018364, Dec 14, 1999

Filed:

May 26, 1998

Appl. No.:

9/084692

Inventors:

Graham S. Poindexter - Old Saybrook CT
R. Thomas Swann - Hamden CT
Marc A. Bruce - Wallingford CT
Mendi A. Morton - Middletown CT
Yazhong Huang - Wallingford CT
James Guy Breitenbucher - Richmond CA

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D40110
A61K 31445

US Classification:

514255

Abstract:

A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of cyanoguanidine derivatives of 4-phenyl-1,4-dihydropyridines of Formula (I). ##STR1## As antagonists of NPY-induced feeding behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.

US Patent:

61774294, Jan 23, 2001

Filed:

Jun 6, 2000

Appl. No.:

9/587817

Inventors:

Yazhong Huang - West Haven CT

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D40112
C07D40312
A61K 31497

US Classification:

51425211

Abstract:

The present invention provides a series of non-peptidergic antagonists of NPY comprising piperidine and piperazine derivatives of 4-phenyl-1,4-dihydropyrazines of the Formula I ##STR1## wherein R, R. sup. 1 X, Y and Z are defined herein. As antagonists of NPY-induced feeding behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.

US Patent:

20220324859, Oct 13, 2022

Filed:

Feb 1, 2021

Appl. No.:

17/164009

Inventors:

- Princeton NJ, US
Louis S. Chupak - Old Saybrook CT, US
Chetan Padmakar Darne - Ewing NJ, US
Min Ding - Stow MA, US
Robert G. Gentles - Killingworth CT, US
Yazhong Huang - Wallingford CT, US
Manjunatha Narayana Rao Kamble - Bangalore, IN
Scott W. Martin - Middletown CT, US
Raju Mannoori - Bangalore, IN
Ivar M. McDonald - Woodstock CT, US
Richard E. Olson - Cambridge MA, US
Hasibur Rahaman - Bangalore, IN
Prasada Rao Jalagam - Bangalore, IN
Saumya Roy - Bangalore, IN
Gopikishan Tonukunuru - Bangalore, IN
Sivasudar Velaiah - Hosur, IN
Jayakumar Sankara Warrier - Bangalore, IN
Xiaofan Zheng - Cheshire CT, US
John S. Tokarski - Princeton NJ, US
Bireshwar Dasgupta - Doylestown PA, US
Kotha Rathnakar Reddy - Warangal West, IN
Thiruvenkadam Raja - Hosur, IN

International Classification:

C07D 471/04

Abstract:

Disclosed are compounds of Formula (I):or a salt thereof, wherein: R, R, R, R, R, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

US Patent:

20230089255, Mar 23, 2023

Filed:

Dec 18, 2020

Appl. No.:

17/786442

Inventors:

- Princeton NJ, US
Joseph L. BENC - Princeton NJ, US
Xinyu WANG - Pennington NJ, US
Upender VELAPARTHI - Princeton Junction NJ, US
Louis S. CHUPAK - Old Saybrook CT, US
Chatan P. DARNE - Ewing NJ, US
Min DING - Stow MA, US
Robert G. GENTLES - Killingworth CT, US
Yazhong HUANG - Wallingford CT, US
Scott W. MARTIN - Middletown CT, US
Ivar M. MCDONALD - Woodstock CT, US
Richard E. OLSON - Cambridge MA, US
Xiaofan ZHENG - Cheshire CT, US
John S. TOKARSKI - Princeton NJ, US
Bireshwar DASGUPTA - Doylestown PA, US
Manjunatha Narayana Rao KAMBLE - Bangalore, IN
Raju MANNOORI - Bangalore, IN
Haslbur RAHAMAN - Bangalore, IN
Prasada Rao JALAGAM - Bangalore, IN
Saumya ROY - Bangalore, IN
Gopikishan TONUKUNURU - Bommasandra Bangalore Karnataka, IN
Sivasudar VELAIAH - Hosur Tamilnadu, IN
Jayakumar Sankara WARRIER - Bangalore, IN
Kotha Rathnakar REDDY - Warangal West Talangana State, IN
Thiruvenkadam RAJA - Tamil Nadu, IN
Denise GRUNENFELDER - Boston MA, US
Michael WICHROSKI - Newbuy MA, US

International Classification:

A61K 31/519
A61K 31/496
A61K 39/395
A61P 35/00

Abstract:

Provided are inhibitors of diacylglycerol kinases (DGK) and methods for treating diseases that would benefit from the stimulation of the immune system, such as cancer and infections diseases, comprising administering a DGK inhibitor in combination with an antagonist of the PD 1/PD-L 1 axis and/or an antagonist of CTLA4.